keyword
MENU ▼
Read by QxMD icon Read
search

Ankylosing spondylitis treatment

keyword
https://www.readbyqxmd.com/read/28521184/one-stage-posterior-grade-4-osteotomy-and-bone-graft-fusion-at-pseudarthrosis-for-the-treatment-of-kyphotic-deformity-with-andersson-lesions-in-ankylosing-spondylitis
#1
Tingxian Ling, Bangjian Zhou, Ce Zhu, Xi Yang, Yueming Song, Zhe Qiang, Limin Liu
OBJECTIVES: The optimal surgical procedure for treating kyphotic deformity with Andersson lesions (ALs) in ankylosing spondylitis (AS) patients is controversial. The one-stage posterior osteotomy and bone graft fusion approach is rarely reported. The aim of the present study was to report a new surgical procedure involving one-stage posterior grade 4 osteotomy and bone graft fusion for the treatment of kyphotic deformity with ALs in AS. PATIENTS AND METHODS: Eleven patients with ALs in AS were enrolled...
May 11, 2017: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/28520640/twenty-four-month-follow-up-of-tocilizumab-therapy-for-refractory-uveitis-related-macular-edema
#2
Marina Mesquida, Blanca Molins, Victor Llorenç, María V Hernández, Gerard Espinosa, Maite Sainz de la Maza, Alfredo Adán
BACKGROUND: To report the 24-month efficacy and safety of the interleukin-6 receptor antagonist tocilizumab (TCZ) for refractory uveitis-related macular edema (ME). METHODS: Data were obtained by standardized chart review. Patients with quiescent uveitis seen at a single tertiary referral center, for whom ME was the principal cause of reduced visual acuity. OUTCOME MEASURES: Central foveal thickness measured by optical coherence tomography; degree of anterior and posterior chamber; inflammation (Standardization of Uveitis Nomenclature Working Group criteria); and visual acuity (Snellen and logarithm of the minimum angle of resolution) were recorded in all patients during TCZ therapy at months 1, 3, 6, 12, 18, and 24...
May 16, 2017: Retina
https://www.readbyqxmd.com/read/28516874/long-term-effects-of-interleukin-17a-inhibition-with-secukinumab-in-active-ankylosing-spondylitis-3-year-efficacy-and-safety-results-from-an-extension-of-the-phase-3-measure-1-trial
#3
Xenofon Baraliakos, Alan J Kivitz, Atul A Deodhar, Jürgen Braun, James C Wei, Eumorphia Maria Delicha, Zsolt Talloczy, Brian Porter
OBJECTIVES: Secukinumab, a fully human anti-IL-17A monoclonal antibody, provided rapid and sustained improvements in signs and symptoms of ankylosing spondylitis (AS) over 2 years in the Phase 3 MEASURE 1 trial. Here, we report efficacy and safety after 3 years of treatment. METHODS: AS subjects completing 2 years of treatment every 4 weeks with subcutaneous secukinumab 150 or 75 mg (following intravenous loading or initial placebo treatment to 16/24 weeks) entered a separate 3-year extension study (NCT01863732)...
May 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28514405/-stable-high-interleukin-17a-concentration-in-patients-with-ankylosing-spondylitis-treated-with-tumor-necrosis-factor-%C3%AE-inhibitors-during-a-year
#4
I Z Gaydukova, A P Rebrov, A V Aparkina, E V Khondkaryan
AIM: To assess changes in the concentration of interleukin-17A (IL-17A) in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor-α (TNFα) inhibitors during a year. SUBJECTS AND METHODS: Examinations were made in 30 patients (22 (73.3%) men) aged 38.35±9.19 years with AS (modified New-York criteria, BASDAI ≥4.0; AS duration, 11.4±9.6 years) and in 20 healthy individuals (12 (60%) men) aged 40.1±7.7 years) (a control group). All the patients were treated with infliximab (remicade, MSD) 5 mg/kg body weight during a year according to the recommended regimen...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28497237/efficacy-of-long-term-nonsteroidal-antiinflammatory-drug-treatment-on-magnetic-resonance-imaging-determined-bone-marrow-oedema-in-early-active-axial-spondyloarthritis-patients
#5
Mei Tang, Leixi Xue, Yueping Shen, Lin Bo, Ru Yang, Jian Wen, Yi Zhang, Zhichun Liu, Jinxiang Fu
To assess the efficacy of long-term treatment with nonsteroidal antiinflammatory drugs (NSAIDs) on bone marrow oedema (BMO) of the sacroiliac joint in newly diagnosed axial spondyloarthritis (SpA) with a symptom duration of less than 4 years, a single-center, open-label study in a cohort of consecutive patients with newly diagnosed axial SpA was conducted. Eligible patients had magnetic resonance imaging (MRI)-determined BMO of the sacroiliac joint at baseline, had a symptom duration of less than 4 years, and were naïve to NSAIDs...
May 11, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28496328/association-between-use-of-disease-modifying-antirheumatic-drugs-and-diabetes-in-patients-with-ankylosing-spondylitis-rheumatoid-arthritis-or-psoriasis-psoriatic-arthritis-a-nationwide-population-based-cohort-study-of-84-989-patients
#6
Hsin-Hua Chen, Der-Yuan Chen, Chi-Chen Lin, Yi-Ming Chen, Kuo-Lung Lai, Ching-Heng Lin
PURPOSE: The aim of this study is to investigate the association between the use of disease-modifying antirheumatic drugs (DMARDs) and diabetes mellitus (DM) in patients with ankylosing spondylitis (AS), rheumatoid arthritis (RA), or psoriasis/psoriatic arthritis (PS/PSA). PATIENTS AND METHODS: This retrospective cohort study used a nationwide, population-based administrative database to enroll 84,989 cases with AS, RA, or PS/PSA who initiated treatment with anti-tumor necrosis factor (anti-TNF) drugs or nonbiologic DMARDs...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28473425/a-nationwide-non-medical-switch-from-originator-infliximab-to-biosimilar-ct-p13-in-802-patients-with-inflammatory-arthritis-1-year-clinical-outcomes-from-the-danbio-registry
#7
Bente Glintborg, Inge Juul Sørensen, Anne Gitte Loft, Hanne Lindegaard, Asta Linauskas, Oliver Hendricks, Inger Marie Jensen Hansen, Dorte Vendelbo Jensen, Natalia Manilo, Jakob Espesen, Mette Klarlund, Jolanta Grydehøj, Sabine Sparre Dieperink, Salome Kristensen, Jimmi Sloth Olsen, Henrik Nordin, Stavros Chrysidis, Dorte Dalsgaard Pedersen, Michael Veedfald Sørensen, Lis Smedegaard Andersen, Kathrine Lederballe Grøn, Niels Steen Krogh, Lars Pedersen, Merete Lund Hetland
OBJECTIVES: According to guidelines, a nationwide non-medical switch from originator (INX, Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). We investigated disease activity before/after switching and retention rates in the DANBIO registry. METHODS: Disease activities 3 months before and after switch and changes over time were calculated...
May 4, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28469937/fat-metaplasia-on-mri-of-the-sacroiliac-joints-increases-the-propensity-for-disease-progression-in-the-spine-of-patients-with-spondyloarthritis
#8
W P Maksymowych, S Wichuk, P Chiowchanwisawakit, R G Lambert, S J Pedersen
OBJECTIVE: We tested the hypothesis that fat metaplasia on MRI of the sacroiliac joints (SIJ) increases the propensity for new bone formation in the spine of patients with spondyloarthritis. METHODS: We assessed baseline T1-weighted and short τ inversion recovery SIJ MRIs from patients in the Follow Up Research Cohort in Ankylosing Spondylitis (FORCAST). Radiographic progression was assessed using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). Structural and inflammatory lesions were scored using the Spondyloarthritis Research Consortium of Canada (SPARCC) SIJ structural and SPARCC SIJ inflammation scores, respectively...
2017: RMD Open
https://www.readbyqxmd.com/read/28441778/gene-expression-analysis-before-and-after-treatment-with-adalimumab-in-patients-with-ankylosing-spondylitis-identifies-molecular-pathways-associated-with-response-to-therapy
#9
Marzia Dolcino, Elisa Tinazzi, Andrea Pelosi, Giuseppe Patuzzo, Francesca Moretta, Claudio Lunardi, Antonio Puccetti
The etiology of Ankylosing spondylitis (AS) is still unknown and the identification of the involved molecular pathogenetic pathways is a current challenge in the study of the disease. Adalimumab (ADA), an anti-tumor necrosis factor (TNF)-alpha agent, is used in the treatment of AS. We aimed at identifying pathogenetic pathways modified by ADA in patients with a good response to the treatment. Gene expression analysis of Peripheral Blood Cells (PBC) from six responders and four not responder patients was performed before and after treatment...
April 24, 2017: Genes
https://www.readbyqxmd.com/read/28435922/spontaneous-corpectomy-and-anterior-arthrodesis-in-lumbar-spine-how-ankylosing-spondylitis-can-resolve-a-vertebral-fracture
#10
Daniele Vanni, Andrea Pantalone, Stefano Di Carlo, Vincenzo Magliani, Pedro Berjano, Vincenzo Salini
Between the 80% and 90% of vertebral fractures in over 65 years people are due to osteoporosis. Over the 30% of patients affected by vertebral osteoporosis fractures needs of surgical treatment and the 12% presents complications requiring an invasive surgical approach. We report an unusual case of spontaneous corpectomy and anterior arthrodesis occurred in a patient suffering from Ankylosing Spondylitis. This event invites us to reflect about the magnitude of the biological power of the bone healing, even in adverse conditions...
March 2017: Journal of Spine Surgery (Hong Kong)
https://www.readbyqxmd.com/read/28434410/dosage-and-duration-of-etanercept-therapy-for-ankylosing-spondylitis-a-meta-analysis
#11
Heeyoung Lee, Younjoo Jung, Seungyeon Song, Jihyung Lee, Hyunjun Shim, Wonku Kang, Eunyoung Kim
OBJECTIVES: We conducted a meta-analysis of recently published randomized controlled trials (RCTs) to identify the most effective and safe etanercept dosing regimen and duration of therapy for the treatment of patients with ankylosing spondylitis (AS). METHODS: We systematically reviewed PubMed, Embase, Cochrane Library, and Web of Science databases for RCTs. The proportion of patients attaining 20 percent improvement (according to the Spondyloarthritis International Society response criteria [ASAS 20]) was evaluated as a primary outcome...
April 24, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28432524/correlation-of-serum-mmp3-and-other-biomarkers-with-clinical-outcomes-in-patients-with-ankylosing-spondylitis-a-pilot-study
#12
Dongyi He, Qi Zhu, Quan Zhou, Qing Qi, Hongmei Sun, Liza M Zachariah, Grace Wang, John D Reveille, Yongtao Guan, Xiaodong Zhou
The studies aimed to assess a set of biomarkers for their correlations with disease activity/severity of patients with ankylosing spondylitis (AS). A total of 24 AS patients were treated with etanercept and prospectively followed for 12 weeks. Serum levels of TNF-α, IFN-γ, TGF-β, IL6, IL15, IL17, MMP3, and MICA were measured at baseline and after treatment. The change of these biomarkers was analyzed for correlations with MRI indices for joint inflammation, Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, AS Disease Activity Score, serum CRP, and ESR...
April 22, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28416826/-surgical-technique-and-early-clinical-outcomes-of-direct-anterior-approach-to-total-hip-arthroplasty
#13
M Lv, J Q Zhang, X S Wang, Y Huang, W Li, C Y Zhang
OBJECTIVE: To describe the surgical technique of direct anterior approach to total hip arthroplasty and to report the early clinical outcomes. METHODS: A series of 100 consecutive, unselected patients who had 116 primary total hip arthroplasty surgeries (16 bilateral) done through direct anterior approach from March 11 2015 to June 21 2016 was reviewed. There were 50 male patients and 50 female patients. The average patient age was 51 years, and the average body mass index was 24...
April 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/28413099/second-line-biologic-therapy-optimization-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis
#14
REVIEW
Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Emanuele Cassarà, Olga Kaloudi, Ennio Giulio Favalli, Andrea Becciolini, Maurizio Benucci, Francesca Li Gobbi, Serena Guiducci, Rosario Foti, Marta Mosca, Delia Goletti
OBJECTIVE: The Italian board for the TAilored BIOlogic therapy (ITABIO) reviewed the most consistent literature to indicate the best strategy for the second-line biologic choice in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA). METHODS: Systematic review of the literature to identify English-language articles on efficacy of second-line biologic choice in RA, PsA, and ankylosing spondylitis (AS). Data were extracted from available randomized, controlled trials, national biologic registries, national healthcare databases, post-marketing surveys, and open-label observational studies...
March 22, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28412700/takayasu-arteritis-and-spondyloarthritis-coincidence-or-association-a-study-of-14-cases
#15
Elodie Rivière, Laurent Arnaud, Mikael Ebbo, Yannick Allanore, Pascal Claudepierre, Emmanuelle Dernis, Jean-Marc Ziza, Corinne Miceli-Richard, Peggy Philippe, Christophe Richez, Martin Soubrier, Rakiba Belkhir, Raphaèle Seror, Xavier Mariette, Stephan Pavy
OBJECTIVE: Spondyloarthritis (SpA) and Takayasu arteritis (TA) are 2 chronic inflammatory diseases; their coexistence in a single patient is uncommon. The aims of our study were to describe clinical features of patients having SpA associated with TA and to identify some characteristics of the types of patients with SpA associated with TA. We also analyzed treatments used in this context. METHODS: This French multicenter retrospective survey called for observations on behalf of the Club Rhumatismes et Inflammations, with a standardized questionnaire established by the investigators...
April 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28410817/medication-adherence-and-persistence-over-time-with-self-administered-tnf-alpha-inhibitors-among-young-adult-middle-aged-and-older-patients-with-rheumatologic-conditions
#16
Gregory S Calip, Sruthi Adimadhyam, Shan Xing, Julian C Rincon, Wan-Ju Lee, Rebekah H Anguiano
OBJECTIVE: Self-injectable TNF inhibitors are increasingly used early in the chronic treatment of moderate to severe rheumatologic conditions. We estimated medication adherence/persistence over time following initiation in young adult and older adult patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. METHODS: We conducted a retrospective cohort study of patients aged 18+ years newly initiating etanercept, adalimumab, certolizumab pegol, or golimumab using the Truven Health MarketScan Database between 2009 and 2013...
March 21, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28407841/cardiovascular-comorbidity-in-inflammatory-rheumatological-conditions
#17
Jürgen Braun, Klaus Krüger, Bernhard Manger, Matthias Schneider, Christof Specker, Hans Joachim Trappe
BACKGROUND: Approximately 1.5 million adults in Germany suffer from an inflammatory rheumatological condition. The most common among these are rheumatoid arthritis and spondyloarthritis-above all axial spondyloarthritis, including ankylosing spondylitis (Bekhterev's disease) and psoriatic arthritis. These systemic inflammatory diseases often affect the heart as well. METHODS: This review is based on pertinent articles retrieved by a selective literature search, on current European guidelines, and on the authors' clinical experience...
March 24, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28405158/patient-experience-with-intravenous-biologic-therapies-for-ankylosing-spondylitis-crohn-s-disease-psoriatic-arthritis-psoriasis-rheumatoid-arthritis-and-ulcerative-colitis
#18
Susan C Bolge, Helen M Eldridge, Jennifer H Lofland, Caitlin Ravin, Philip J Hart, Michael P Ingham
OBJECTIVE: The objective of this study was to describe patient experience with intravenous (IV) biologics for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, or ulcerative colitis. METHODS: Semi-structured telephone interviews were conducted in 405 patients with these autoimmune diseases who were receiving an IV biologic to treat their disease. RESULTS: On a 7-point scale (1= not at all satisfied; 7= very satisfied), mean satisfaction with IV medication was rated 6...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28403136/influence-of-cyp2c9-and-cox-2-genetic-polymorphisms-on-clinical-efficacy-of-non-steroidal-anti-inflammatory-drugs-in-treatment-of-ankylosing-spondylitis
#19
Yu Wang, Xiao-Dong Yi, Hai-Lin Lu
BACKGROUND The aim of this study was to evaluate the relationships of CYP2C9 and COX-2 genetic polymorphisms with therapeutic efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) in treatment of ankylosing spondylitis (AS). MATERIAL AND METHODS We enrolled 130 AS inpatients and outpatients in the Arthritis and Rheumatism Department of Peking University First Hospital and 106 healthy people getting routine check-ups between September 2013 and July 2014. CYP2C9 and COX-2 genetic polymorphisms were detected by PCR-RFLP...
April 12, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28394822/janus-kinase-signal-transducer-and-activator-of-transcription-pathways-in-spondyloarthritis
#20
Smriti K Raychaudhuri, Siba P Raychaudhuri
PURPOSE OF REVIEW: Cytokines are major drivers of autoimmunity, and biologic agents targeting cytokines have revolutionized the treatment of immune-mediated diseases. Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway represents a group of several intracellular molecules with a key role in signal pathways activated by growth factors and cytokines. These kinase proteins are associated with the signaling process of multiple key cytokines, which regulates various T-cell subpopulations and their effector cytokines...
April 7, 2017: Current Opinion in Rheumatology
keyword
keyword
53915
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"